Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FSME-IMMUN NEW · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| FSME-IMMUN NEW 0.25 ml | BIOLOGICAL | - |
Inclusion Criteria: Male and female children and adolescents will be eligible for participation in this study if: * they are aged 1 year (from the 1st birthday) to \< 16 years (to the last day before the 16th birthday); * they are clinically healthy, (i. e. the physician would have no reservations...
FSME-IMMUN NEW is used for Tick-borne Encephalitis, a viral infection of the central nervous system. It is being developed as a preventive measure for this disease, which is transmitted by tick bites in endemic areas.
FSME-IMMUN NEW is developed by Pfizer, Inc., a global biopharmaceutical company. Pfizer is listed on the New York Stock Exchange under the ticker symbol PFE.
FSME-IMMUN NEW is in Phase 3 clinical development. It is an investigational product and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed.
FSME-IMMUN NEW has one completed Phase 3 trial, NCT00161863, titled "Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years." The study was conducted in Austria, Germany, and Poland.
Yes, FSME-IMMUN NEW is a monoclonal antibody. It is being studied for the prevention of Tick-borne Encephalitis, and the completed Phase 3 trial focused on its safety in children and adolescents aged 1 to 15 years.